Inlyta — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of advanced renal cell carcinoma (ICD-10: C64)
• using as first-line with avelumab OR pembrolizumab OR as single agent after one prior systemic therapy failure

Reauthorization criteria

• prescriber attests member is tolerating therapy and has experienced a therapeutic response (disease improvement or delayed disease progression)

Approval duration

12 months